Adaptive Biotechnologies announces 90 abstracts to be presented at ASH meeting

Adaptive Biotechnologies (ADPT) announced that its next-generation sequencing-based clonoSEQ test for measurable residual disease assessment will be included in 89 abstracts, including 36 oral presentations, at the 67th Annual Meeting of the American Society of Hematology taking place Dec. 6-9, 2025, in Orlando. Key highlights include: Abstracts featuring clonoSEQ MRD data span multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, and other blood cancers, underscoring its position as the most widely used and validated next-generation sequencing-based MRD test in lymphoid malignancies. More than 17 presentations demonstrate how clonoSEQ MRD assessment is informing patient treatment decisions in real world clinical practice, including studies to guide treatment in ALL, CLL, MM, MCL and DLBCL. Continued expansion of clonoSEQ use in clinical trials to enable the deepest assessment of treatment responses for novel regimens and across a wide range of therapeutic modalities, including CAR T, bispecific antibodies, and other targeted therapies.